<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737957</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-LFPRP</org_study_id>
    <nct_id>NCT01737957</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Low-Fluence PRP for PDR</brief_title>
  <official_title>Safety and Efficacy of Single-session, Low-fluence Panretinal Photocoagulation (PRP) for Proliferative Diabetic Retinopathy (PDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of a single session of low-fluence panretinal
      photocoagulation when compared to full-fluence PRP. Hypothesis: a single-session of
      low-fluence PRP will be safe regarding the progression of macular edema and the presence of
      adverse events, and will efficiently induce regression of neovascularization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Macular thickness change</measure>
    <time_frame>Base-line, 1 week, 6 weeks, 12 weeks, 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of macular thickness changes by spectral domain optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Presence or absence of adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Regression of neovessels, change over time</measure>
    <time_frame>Base-line, 1 week, 6 weeks, 12 weeks, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Regression of neovessels observed by fluorescein angiography</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Low-fluence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full-fluence</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-fluence PRP with 532nm green LASER</intervention_name>
    <description>To administer low-fluence PRP in a single session for PDR</description>
    <arm_group_label>Low-fluence</arm_group_label>
    <other_name>PURE-POINT LASER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Full-Fluence PRP with 532nm LASER</intervention_name>
    <description>To administer full-fluence PRP in two sessions for PDR</description>
    <arm_group_label>Full-fluence</arm_group_label>
    <other_name>PURE-POINT LASER</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or type 2 diabetics

          -  Proliferative diabetic retinopathy

        Exclusion Criteria:

          -  Previous treatment with PRP

          -  Media opacities

          -  Previous treatment for macular edema (LASER or intravitreal injections)

          -  Recent (less than 6 months) ophthalmic surgery

          -  Only eyes

          -  Intra-retinal or sub-retinal fluid with foveal involvement

          -  Chronic renal failure

          -  History of liver or pancreatic transplant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Salcedo-Villanueva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación Para Evitar la Ceguera en México</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoko Burgoa</last_name>
      <phone>(52) 55 10841400</phone>
      <phone_ext>1172</phone_ext>
      <email>yokoburgoa@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo Salcedo-Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 28, 2012</lastchanged_date>
  <firstreceived_date>November 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asociación para Evitar la Ceguera en México</investigator_affiliation>
    <investigator_full_name>Guillermo Salcedo-Villanueva</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Proliferative Diabetic retinopathy</keyword>
  <keyword>Pan-retinal photocoagulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
